Sanjivani Paranteral Ltd. · BSE:SANJIVIN
Sanjivani Paranteral — Q4 FY25 Earnings Presentation
38 slides from Sanjivani Paranteral's earnings presentation, May 27, 2025
Slide 1: Cover letter to BSE
Date: 27th February, 2025 To, Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 531569 Sub: Investor Presentation for the Quarter and Year ended March 31, 2025. Dear Sir/ Madam, Please find enclosed herewith Investor Presentation of S
Slide 2: Sanjivani Paranteral Ltd Investor Presentation Q4 & FY25
Sanjivani Paranteral Ltd Investor Presentation Q4 & FY25 s a n j i v a n i . c o . i n
Slide 3: Table of Content
04 Market Overview 22 Global Footprint 07 About The Company 24 Product Portfolio 13 Manufacurting Plant 28 Financials 16 36 TABLE OF CONTENT CDMO Key Clients Stock Information 18 Company’s Segment & Revenue Mix s a n j i v a n i . c o . i n
Slide 4: Key Financial Highlights
Key Financial Highlights Q4 FY25 FY25 Rs. In Mn. Revenue from Operations EBIDTA* Revenue from Operations EBIDTA* (up 41.3% Y-o-Y) (up by 37.9% Y-o-Y) (up 28.8% Y-o-Y) (up by 32.1% Y-o-Y) 181.8 30.5 701.0 115.7 PAT Domestic & Export PAT Domestic & Export (up by 74.4% Y-o-Y) (share in revenue) (up by
Slide 5: Market Overview
MARKET OVERVIEW s a n j i v a n i . c o . i n
Slide 6: Global Medicine Market
Global Medicine Market Use of medicines region wise, Defined Daily Doses (DDD) CAGR % Country Name/Year 2018 2019 2020 2021 2022 2023 2024E 2025E 2026E 2027E 2028E 2024-2028 Asia-Pacific 451 461 477 507 547 538 559 580 598 618 637 3.4% Latin America 342 357 438 447 448 461 473 484 489 496 506 1.9% W
Slide 7: Global Medicine Market
Global Medicine Market Defined Daily Doses Global use of Global spending (DDD) in billions medicines on medicine 814 28% 73% 414 14% 35% 2018 2028 2018 2028 2018 2028 Source: IQVIA Institute, Dec 2023. Investor Presentation Q4 & FY25 www.sanjivani.co.in 6
Slide 8: About The Company
ABOUT THE COMPANY s a n j i v a n i . c o . i n
Slide 9: About Us
About Us Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and four manufacturing plants at Navi Mumbai, Dehradun, Pimpri & Czech Republic, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major t
Slide 10: Significant Milestone of Sanjivani
Significant Milestone of Sanjivani 2022 2025 Achieved milestone of adding 100th product in the portfolio 1. Initial commercial batches started in Prague 1996 2. Pune plant validation batches started 1. Navi Mumbai Plant 2. Listing no BSE April’96 2023 1. Entered into a JV with Alevia Healthcare 2009
Slide 11: Vision, Mission, Values
Vision of the Company VISION MISSION To be one of India’s best research-based pharmaceutical companies, through focus on quality Creating a world-class organization offering and customer satisfaction. products, services & paradigms that open To bring forth a new paradigm of products & services which
Slide 12: Sanjivani Competitive Advantage
Sanjivani Competitive Advantage We have a compact and highly adaptable presence in As pioneers in injectable manufacturing in India, we have India, allowing us to be exceptionally nimble and agile navigated the industry’s regulatory evolution from its early, less stringent days. This experience allo
Slide 13: Experienced Management
Experienced Management Mr. Ashwani Khemka Mrs. Mrunmai Sarvankar Mr. Srivardhan Khemka Chairman & Managing Director Director Executive Director Mr. Abhay Shah Ms. Monika A. Singhania Mr. Pritesh Jain Independent Director Independent Director Chief Financial Officer Investor Presentation Q4 & FY25 ww
Slide 14: Manufacturing Plant
MANUFACTURING PLANT s a n j i v a n i . c o . i n
Slide 15: Manufacturing Plant – Alevia HealthCare, Czech Republic
Manufacturing Plant – Alevia HealthCare, Czech Republic, Plant Investor Presentation Q4 & FY25 www.sanjivani.co.in 14
Slide 16: IV Manufacturing Plant – SPL Infusion, Pune
IV Manufacturing Plant – SPL Infusion Private Limited, Pune Plant Investor Presentation Q4 & FY25 www.sanjivani.co.in 15
Slide 17: CDMO Key Clients
CDMO KEY CLIENTS s a n j i v a n i . c o . i n
Slide 18: CDMO Key Clients
CDMO Key Clients Injectables Oral & Nutraceuticals Investor Presentation Q4 & FY25 www.sanjivani.co.in 17
Slide 19: Company's Segment & Revenue Mix
COMPANY’S SEGMENT & REVENUE MIX s a n j i v a n i . c o . i n
Slide 20: Product Category Mix (%)
Product Category Mix (%) 3.6% 1.0% Q4 FY25 Q4 FY24 27.0% Injectables Injectables 33.4% Tablets Tablets Nutraceuticals 63.0% 71.9% Nutraceuticals 4.2% 1.7% FY24 FY25 Injectables 29.1% Injectables 37.1% Tablets 58.7% Tablets Nutraceuticals 69.3% Nutraceuticals Investor Presentation Q4 & FY25 www.sanji
Slide 21: Geographical Mix (%)
Geographical Mix (%) 27.5% Q4 FY25 30.0% Q4 FY24 Domestic Domestic 70.0% Exports 72.5% Exports 18.5% FY25 24.9% FY24 Domestic Domestic Exports Exports 75.1% 81.5% Investor Presentation Q4 & FY25 www.sanjivani.co.in 20
Slide 22: Region-wise Mix (%)
Region-wise Mix (%) 3.1% 2.8% Q4 FY25 Q4 FY24 31.1% 30.1% Latin America 31.3% Latin America 33.1% Middle East & Africa Middle East & Africa India & Subcontinent India & Subcontinent CIS Countries CIS Countries 33.6% 34.9% 1.3% 6.9% FY25 FY24 28.7% 26.0% 26.6% Latin America Latin America Middle East
Slide 23: Global Footprint
GLOBAL FOOTPRINT s a n j i v a n i . c o . i n
Slide 24: Global Footprint
Global Footprint Dehradun Prague CIS Countries Navi Mumbai India Central America Latin Pimpri, Pune America Navi Mumbai, Dehradun, Pimpri & Prague Investor Presentation Q4 & FY25 www.sanjivani.co.in 23
Slide 25: Product Portfolio
PRODUCT PORTFOLIO s a n j i v a n i . c o . i n
Slide 26: Product Portfolio
Product Portfolio Investor Presentation Q4 & FY25 www.sanjivani.co.in 25
Slide 27: Product Portfolio
Product Portfolio Urologics Anesthetics Anesthetics Anti Anti Thyroid Convulsants Agent Anti Anti Anti Anti Anti Anti-lepemic Anti Fungal Emetics Depressants Histamines Diabetic Agent Fibrinolytics Anti-bacterials Anti-spasmodic Anti Vitamin Skeletal Analgesic & Hypertensive Agent Supplement Muscle
Slide 28: Product Portfolio
Product Portfolio Non-opioid Antacids Antiseptics Nsaids Corticosteroids Analgesics Diuretics Immunosupress Narcotic Hormone Topical Anti Anxiety ants Corticosteroids Antibiotic Antipsychotic Anti Viral Narcotics Anti- Muscle Relaxant Investor Presentation Q4 & FY25 www.sanjivani.co.in 27
Slide 29: Financials
FINANCIALS s a n j i v a n i . c o . i n
Slide 30: Segment-wise Revenue
Segment-wise Revenue (Injectables, Oral & Nutraceuticals) Rs. In Mn. INJECTABLES ORALS 129.2 130.8 49.1 42.9 81.1 34.1 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 NUTRACEUTICALS 10.2 4.6 1.9 Q4FY24 Q3FY25 Q4FY25 Investor Presentation Q4 & FY25 www.sanjivani.co.in 29
Slide 31: Quarterly Financials - Revenue, EBITDA & Margin, PAT & Margin
Quarterly Financials - Revenue, EBITDA & Margin, PAT & Margin Rs. In Mn. REVENUE* EBIDTA** & EBIDTA Margin 181 174 182 17.2% 16.8% 164 16.5% 14.7% 129 17.9% 22 24 32 29 31 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 PBT & PBT Margin PAT & PAT Margin 15.7% 13.8% 14.2% 23 22
Slide 32: Q4 & FY25 Profit & Loss Statement
Q4 & FY25 Profit & Loss Statement Particulars (Rs. In Mn.) Q4 FY25 Q4 FY24 YoY% Q3 FY25 QoQ% FY25 FY24 YoY% Revenue From Operations 181.8 128.6 41.3% 173.5 4.8% 701.0 544.1 28.8% Other Income 4.3 0.5 713.0% 3.1 36.9% 12.1 5.2 134.6% Total Income 186.1 129.2 44.1% 176.6 5.4% 713.1 549.3 29.8% COGS 93
Slide 33: Standalone Balance Sheet as on 31st March 2025
Standalone Balance Sheet as on 31st March 2025 Particulars (Rs. In Mn.) Mar-25 Mar-24 Particulars (Rs. In Mn.) Mar-25 Mar-24 Equities & Liabilities Assets Non-Current Assets Equity Share Capital 118.8 116.8 Property, Plant & Equipment 205.6 99.4 Other Equity 261.2 162.1 Other Intangible Assets 0.0 0
Slide 34: Yearly Financials
Yearly Financials Revenue, EBITDA & Margin, PAT & Margin Rs. In Mn. REVENUE* EBIDTA** & EBIDTA Margin 701 19.5% 17.4% 544 16.1% 16.5% 355 306 60 62 88 116 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 PAT & PAT Margin EPS In Rs. 6.9 15.7% 12.5% 5.3 11.2% 11.4% 4.9 4.5 48 45 62 81 FY22 FY23 FY24 FY25 FY22
Slide 35: Yearly Financials
Yearly Financials INVENTORY DAYS RECEIVABLES DAYS PAYABLES DAYS 125 87 339 105 94 270 52 138 32 20 74 15 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 CASH CONVERSION CYCLE DAYS BOOK VALUE per share, Rs 83 43 3.2 2.4 0.3 -144 -229 -0.8 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Inventory
Slide 36: Long Term Growth Drivers
Long Term Growth Drivers 1 Expand Product Portfolio 2 Strategic partnerships & Collaborations Expand into New Geographies 3 Therapeutic Diversification 4 Investor Presentation Q4 & FY25 www.sanjivani.co.in 35
Slide 37: Stock Information
Stock Information Shareholding Pattern as on 31st March 2025 Stock Information (as on 31st March 2025) Market Cap. (in crores) 285 28.9 38.6 Stock Price 239.7 6.2 52 Week (High / Low) 388.5 / 143.9 18.2 8.2 BSE – Symbol 531569 Free Float (No. of Shares) 84,51,239 Promoter Institutions HNI Corporate
Slide 38: Thank You
THANK YOU Sanjivani Paranteral Limited 205, P.N.Kothari Industrial Estate, L.B.S. Marg Bhandup (W), Mumbai- 400078, India. Ph: +91-22-20812600 / 25620515 Email: [email protected] Jill Chandrani +91 7506023955 Email: [email protected] 215, Shivshakti Industrial Estate, J.R Boricha Marg, Lower